financetom
Business
financetom
/
Business
/
German exports rise in August, defying expectations of decline
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
German exports rise in August, defying expectations of decline
Oct 10, 2024 9:54 PM

BERLIN (Reuters) -German exports rose in August due to strong demand particularly from the United States and the United Kingdom, official data showed on Wednesday, defying market expectations of a decline.

Exports rose by 1.3% in August compared with the previous month, data from the federal statistics office showed.

The result compared with a forecast 1.0% decrease in a Reuters poll.

"The second slight increase in exports in a row is a small glimmer of hope, but no reason to sound the all-clear," said Volker Treier, head of foreign trade at the German Chamber of Commerce DIHK.

He said the export economy is still under pressure due to the high costs for energy, taxes and personnel, but also excessive bureaucracy.

"Fundamental improvements are urgently needed in Germany as a business location if the German export engine is to pick up in the long term," Treier said.

The foreign trade surplus broadened to 22.5 billion euros ($24.69 billion) in August from 16.9 billion euros in July.

"This is a punchy gain in the surplus, but our estimates still suggest that the inflation-adjusted trade surplus in goods is on track for a decline in the third quarter due mainly to a big fall in July, weighing on GDP growth," said Claus Vistesen, chief eurozone economist at Pantheon Macroeconomics.

Germany's trade surplus jump was boosted mainly by a sharp fall in imports, which fell by 3.4% on the month.

On the other hand, exports to EU countries rose by 0.8% on the month and exports to third countries increased by 1.9%, the data showed.

Exports of goods to the U.S. were up 5.5% compared with July and exports to the U.K. rose by 5.7%.

(Reporting by Chiara Holzhaeuser in Gdansk and Maria Martinez in Berlin, Editing by Miranda Murray and Muralikumar Anantharaman)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
NextDecade Executes Purchase Deal With Aramco Unit for Offtake From Rio Grande LNG Train 4
NextDecade Executes Purchase Deal With Aramco Unit for Offtake From Rio Grande LNG Train 4
Apr 8, 2025
09:00 AM EDT, 04/08/2025 (MT Newswires) -- NextDecade ( NEXT ) said Tuesday that it has executed a 20-year liquefied natural gas sale and purchase agreement with a unit of Saudi Arabian national oil company Aramco. NextDecade ( NEXT ) said the agreement states that the Aramco unit will buy 1.2 million metric tons per annum of LNG for 20...
South Korea's acting president talks with Trump ahead of 25% tariff
South Korea's acting president talks with Trump ahead of 25% tariff
Apr 8, 2025
By Ju-min Park and Jihoon Lee SEOUL (Reuters) -South Korea's acting President Han Duck-soo on Tuesday spoke with President Donald Trump over the phone, a day before Trump's 25% tariff on the Asian ally is scheduled to kick in. It is the first time Trump spoke with any of South Korea's acting leaders since he took office in January, while...
Recursion Pharmaceuticals Doses First Patient in Phase 1 Trial of Potential B-Cell Lymphoma Treatment
Recursion Pharmaceuticals Doses First Patient in Phase 1 Trial of Potential B-Cell Lymphoma Treatment
Apr 8, 2025
08:59 AM EDT, 04/08/2025 (MT Newswires) -- Recursion Pharmaceuticals ( RXRX ) said Tuesday the first patient has been dosed in a phase 1 clinical study of REC-3565 for the potential treatment of relapsed or refractory B-cell lymphomas. The investigational drug has demonstrated evidence of durable tumor regression in preclinical trials as a monotherapy and in combination with a BTK...
Copyright 2023-2026 - www.financetom.com All Rights Reserved